AU2003229043B2 - Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof - Google Patents

Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof Download PDF

Info

Publication number
AU2003229043B2
AU2003229043B2 AU2003229043A AU2003229043A AU2003229043B2 AU 2003229043 B2 AU2003229043 B2 AU 2003229043B2 AU 2003229043 A AU2003229043 A AU 2003229043A AU 2003229043 A AU2003229043 A AU 2003229043A AU 2003229043 B2 AU2003229043 B2 AU 2003229043B2
Authority
AU
Australia
Prior art keywords
ethyl
oxo
carboxylic acid
dihydroquinoline
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003229043A
Other languages
English (en)
Other versions
AU2003229043A1 (en
Inventor
Kelvin W. Gee
Derk J. Hogenkamp
Timothy B.C. Johnstone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2003229043A1 publication Critical patent/AU2003229043A1/en
Application granted granted Critical
Publication of AU2003229043B2 publication Critical patent/AU2003229043B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
AU2003229043A 2002-05-14 2003-05-12 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof Ceased AU2003229043B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38064102P 2002-05-14 2002-05-14
US60/380,641 2002-05-14
PCT/US2003/014948 WO2003097564A2 (en) 2002-05-14 2003-05-12 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Publications (2)

Publication Number Publication Date
AU2003229043A1 AU2003229043A1 (en) 2003-12-02
AU2003229043B2 true AU2003229043B2 (en) 2008-12-04

Family

ID=29549994

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003229043A Ceased AU2003229043B2 (en) 2002-05-14 2003-05-12 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Country Status (16)

Country Link
US (2) US7355047B2 (enExample)
EP (1) EP1503759B1 (enExample)
JP (1) JP4532263B2 (enExample)
KR (1) KR20040107525A (enExample)
CN (1) CN1652784A (enExample)
AT (1) ATE417613T1 (enExample)
AU (1) AU2003229043B2 (enExample)
BR (1) BR0309965A (enExample)
CA (1) CA2484308A1 (enExample)
DE (1) DE60325347D1 (enExample)
DK (1) DK1503759T3 (enExample)
ES (1) ES2319176T3 (enExample)
IL (1) IL164734A0 (enExample)
MX (1) MXPA04011156A (enExample)
NZ (1) NZ536061A (enExample)
WO (1) WO2003097564A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2484308A1 (en) * 2002-05-14 2003-11-27 The Regents Of The University Of California Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
UA85711C2 (ru) * 2004-05-06 2009-02-25 Зе Регентс Оф Зе Юниверсити Оф Калифорния Замещенные енаминоны, их производные и их применение
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
MX2007012335A (es) * 2005-04-11 2007-11-21 Hoffmann La Roche (3,4-dihidro-quinazolina-2-il)-indano-1-il-aminas.
MX2007013606A (es) * 2005-05-04 2007-12-10 Hoffmann La Roche (3,4-dihidro-quinazolin2-il)-(2-ariloxi-etil)-aminas que tienen una actividad en el receptor 5-ht.
ATE475650T1 (de) * 2005-12-05 2010-08-15 Merck Sharp & Dohme Positive allosterische chinolon-m1- rezeptormodulatoren
CN101374849A (zh) * 2005-12-24 2009-02-25 沃泰克斯药物股份有限公司 作为abc转运蛋白调控剂的喹啉-4-酮衍生物
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
WO2007106537A2 (en) * 2006-03-13 2007-09-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
EP1886996A1 (en) * 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
KR20090035744A (ko) * 2006-08-10 2009-04-10 페레르 인터내쇼날 에스.에이. Ｇａｂａ 수용체의 친화력을 갖는 1ｈ-퀴놀린-4-원 화합물,제조방법, 사용방법 및 조성물
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
ES2399071T3 (es) 2006-10-16 2013-03-25 Bionomics Limited Nuevos compuestos ansiolíticos
WO2009040377A2 (en) * 2007-09-27 2009-04-02 Ge Healthcare Limited Imaging agents
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2009307892A1 (en) * 2008-10-23 2010-04-29 Merck Sharp & Dohme Corp. Fused heterocyclic M1 receptor positive allosteric modulators
KR101727762B1 (ko) 2009-03-20 2017-04-17 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
US20120093917A1 (en) * 2009-04-02 2012-04-19 Robert Hromas Metnase and intnase inhibitors and their use in treating cancer
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP2014510065A (ja) 2011-03-02 2014-04-24 バイオノミックス リミテッド 治療薬としての新規な小分子
WO2012116410A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
JP6055817B2 (ja) 2011-05-12 2016-12-27 バイオノミックス リミテッド ナフチリジンの調製方法
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
CN107501107A (zh) * 2017-09-26 2017-12-22 兰亚朝 喹诺酮药物的中间体合成方法
CN111269131B (zh) * 2020-03-12 2021-12-28 江苏飞宇医药科技股份有限公司 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000068202A1 (en) * 1999-05-06 2000-11-16 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
JPS5715760B2 (enExample) * 1974-06-11 1982-04-01
US4390541A (en) 1980-12-19 1983-06-28 Lilly Industries Limited Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
GB0127349D0 (en) * 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
CA2484308A1 (en) * 2002-05-14 2003-11-27 The Regents Of The University Of California Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000068202A1 (en) * 1999-05-06 2000-11-16 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Uno, T. et al 1987 Journal of Medicinal Chemistry 30(12):2163-2169 *

Also Published As

Publication number Publication date
EP1503759A4 (en) 2006-02-15
AU2003229043A1 (en) 2003-12-02
WO2003097564A3 (en) 2004-02-26
US20060178516A1 (en) 2006-08-10
ES2319176T3 (es) 2009-05-05
BR0309965A (pt) 2005-03-01
US7355047B2 (en) 2008-04-08
WO2003097564A2 (en) 2003-11-27
IL164734A0 (en) 2005-12-18
JP2005535592A (ja) 2005-11-24
CN1652784A (zh) 2005-08-10
JP4532263B2 (ja) 2010-08-25
NZ536061A (en) 2008-09-26
ATE417613T1 (de) 2009-01-15
HK1072905A1 (en) 2005-09-16
EP1503759A2 (en) 2005-02-09
DE60325347D1 (de) 2009-01-29
EP1503759B1 (en) 2008-12-17
US20080176897A1 (en) 2008-07-24
MXPA04011156A (es) 2005-02-17
CA2484308A1 (en) 2003-11-27
KR20040107525A (ko) 2004-12-20
DK1503759T3 (da) 2009-04-14

Similar Documents

Publication Publication Date Title
EP1503759B1 (en) Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
RU2309149C2 (ru) Способ получения 7-замещенного-3-хинолин и 3-хинол-4-он карбонитрилов
EP0918774B9 (en) Androgen receptor modulator compounds and methods
Wentland et al. Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6, 8-difluoro-1, 4-dihydro-7-(2, 6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxylic acid and related derivatives
JPH09500628A (ja) 縮合シクロアルキルイミダゾピリジン
JPH0232058A (ja) ４―アミノ―３―カルボキシキノリン類およびナフチリジン類、製法および医薬用途
EP0237955A2 (en) Quinolonecarboxylic acid derivatives and their preparation
BG108325A (bg) Нови 4-анилинохинолин-3-карбоксамиди
JP2002544197A (ja) 置換４−オキソ−キノリン−３−カルボキサミド：ｇａｂａ脳受容体リガンド
KR101278383B1 (ko) 퀴놀론 화합물 및 제약 조성물
US5223513A (en) Quinoline derivatives, their production and use
EP2350014A1 (en) Glycine b antagonists
EP2264035A1 (en) Glycine B antagonists
US5916898A (en) Phenanthroline derivatives
CA2419966A1 (en) Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor
US5523407A (en) Quinoline derivatives, their production and use as ACAT inhibitors
KR20150083845A (ko) 신규한 항―침습 화합물
EP0160578A1 (en) 1,8-Naphthyridine derivatives
US6743817B2 (en) Substituted fused pyrroleimines and pyrazoleimines
Sato et al. Discovery of benzo [f] pyrido [4, 3-b][1, 4] oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model
HK1072905B (en) Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
JP2005516901A (ja) １Ｈ−ピロロ［３，２−ｂ］ピリジン−３−カルボン酸アミド化合物
US6673811B1 (en) 1H-pyrrolo [3,2-b] pyridine-3-carboxylic acid amines as GABAA receptor ligands
JP2006225379A (ja) キノロン誘導体又はその塩の製造法
US20080032975A1 (en) Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired